Stock KYTX KYVERNA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Real-time Estimate Cboe BZX
Other stock markets
 09:58:29 2024-06-13 am EDT 		5-day change 1st Jan Change
16.02 USD +16.63% Intraday chart for Kyverna Therapeutics, Inc. +6.44% 0.00%
May. 14 Kyverna Therapeutics Q1 Loss Narrows MT
May. 14 Kyverna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
PR
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
PR
First-in-Disease Use of Kyverna Therapeutics KYV-101 in Patients with Progressive Multiple sclerosis Published in Med1
AQ
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
PR
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
PR
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
PR
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KYTX Stock
  4. News Kyverna Therapeutics, Inc.
  5. Press Releases